Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Paysign, Inc.

Ticker
PAYS
Sector
Industry
Report date
November 10, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Paysign reported record third quarter 2026 revenue of $30.8 million, a 43% increase year-over-year, and discussed growth in its patient-affordability business segment targeting $117 million revenue. The company’s Q3 2026 earnings call provided operational insights and reaffirmed its market position.

Recent developments:
  • Paysign reported record third quarter 2026 revenue of $30.8 million, up 43% year-over-year [N2].
  • The company targets $117 million revenue driven by growth in its patient-affordability business segment [N4].
  • Paysign’s Q3 2026 earnings call transcript detailed operational performance and strategic initiatives [N1].
Overview

Paysign, Inc., headquartered in Nevada and trading on Nasdaq under PAYS, provides prepaid card products and processing services across corporate, consumer, and government sectors. Its Paysign® brand encompasses a broad suite of prepaid card solutions including corporate incentives, healthcare payment assistance, general purpose reloadable cards, and demand deposit accounts. The company also offers Apherion™, a cloud-based technology platform for blood and plasma collection organizations. Paysign’s revenue streams include cardholder fees, interchange, program management fees, transaction processing fees, breakage, and settlement income. The company services millions of cardholders and nearly half of U.S. plasma collection centers. Its technology platform supports bilingual customer service and multiple digital engagement channels. Recent financial data shows positive net income and liquidity ratios as of Q3 2026.

Executive summary

Paysign, Inc. is a vertically integrated prepaid card and payment processing company serving corporate, consumer, and government clients through its Paysign® brand. It also offers life science technology solutions under the Apherion™ brand. The company derives revenue from multiple prepaid card lifecycle stages and related services. As of September 30, 2026, Paysign reported net income of $6.7 million and a current ratio of 1.15. Recent news highlights record Q3 2026 revenue of $30.8 million, a 43% increase year-over-year, and a revenue target of $117 million driven by growth in patient-affordability solutions. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for PAYS

Bull case model:

Paysign’s growth in patient-affordability products and expansion in corporate incentive and disbursement programs demonstrate its ability to capture emerging market opportunities. The company’s record Q3 2026 revenue and targeted $117 million revenue milestone reflect operational execution and market acceptance. Its scalable technology platform and broad product offerings position it to serve diverse client needs efficiently. Continued innovation in fintech and healthcare payment solutions could support sustained business expansion.

Bear case model:

Paysign faces risks related to regulatory changes in the prepaid card and healthcare payment industries, which could impact product offerings and revenue streams. Competition from other payment processors and fintech firms may pressure margins and market share. The company’s reliance on issuing bank partners and payment networks introduces dependency risks. Operational challenges in scaling customer service and technology infrastructure could affect client satisfaction. Economic factors influencing corporate and government spending may also impact demand for prepaid card solutions.

Moat:

Paysign’s moat is supported by its vertically integrated prepaid card platform with end-to-end lifecycle management, strong fintech capabilities, and a diversified product suite tailored to multiple sectors including pharmaceuticals and plasma donation. Its established relationships with issuing banks and payment networks, combined with proprietary technology and analytics, create barriers to entry. The company’s significant market share in plasma donor payments and specialized patient affordability solutions further strengthen its competitive position. Additionally, its in-house bilingual customer service and integrated communication tools enhance client retention and user experience.

Risks overview
Risks summary
Regulatory changes and competitive pressures represent the most significant risks to Paysign’s business model and growth prospects.
Risks details:

• Regulatory Risk: Changes in financial regulations or healthcare payment policies could affect Paysign’s prepaid card products and patient affordability solutions.
• Competitive Risk: Intense competition from other payment processors and fintech companies may limit growth and compress margins.
• Operational Risk: Dependence on issuing bank partners and payment networks creates potential vulnerabilities in service delivery and revenue.
• Market Risk: Economic downturns or reduced corporate/government spending could decrease demand for prepaid card programs.

FINAL FORECAST FOR PAYS

Final take one line
Paysign exhibits very high visibility with detailed disclosures on its prepaid card and payment processing business, supported by strong recent revenue growth and expanding patient-affordability solutions.
Final take 12 to 24 month view

Business trends: Growth in prepaid card usage across corporate, healthcare, and plasma donor markets, with increasing adoption of patient-affordability products.
Execution milestones: Achieving record quarterly revenues, expanding cardholder base, and scaling patient-affordability business segment.
Key risks: Regulatory changes impacting prepaid and healthcare payment products, competitive pressures, and operational dependencies on banking partners.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Paysign, Inc. is a vertically integrated provider of prepaid card products and processing services for corporate, consumer, and government entities, operating under the Paysign® brand [S1].
  • The company also offers life science technology solutions targeting blood and plasma collection organizations under the Apherion™ brand, generating revenue from licensing, hosting, and consulting fees [S1].
  • Paysign operates a high-availability payment solutions platform with fintech capabilities that manage transaction processing, cardholder enrollment, value loading, account management, data analytics, and customer service [S1].
  • The company’s prepaid card offerings include corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, pharmaceutical payment assistance, demand deposit accounts accessible with debit cards, and software solutions for blood and plasma collection organizations [S1].
  • Paysign’s revenue streams include cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage, and settlement income [S1].
  • As of December 31, 2025, Paysign had approximately 8.4 million cardholders participating in about 670 card programs [S1].
  • The company services approximately 48% of plasma collection centers in the U.S. and Puerto Rico with its plasma donor payment solutions [S1].
  • Paysign’s technology platform supports bilingual customer service, IVR, SMS alerts, and two-way SMS messaging, enhancing cardholder experience [S1].
  • Recent financial data as of September 30, 2026, shows net income of $6.7 million, basic EPS of $0.12, diluted EPS of $0.11, current assets of $314.9 million, current liabilities of $273.0 million, a current ratio of 1.15, and a cash ratio of 0.03 [S2].
  • Paysign reported record third quarter 2026 revenue of $30.8 million, up 43% year-over-year [N2].
  • The company targets $117 million revenue driven by growth in its patient-affordability business segment [N4].
  • Paysign’s Q3 2026 earnings call and other quarterly earnings calls provide detailed operational and financial insights [N1, N6, N7].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
  • N1
  • N6
  • N7
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-25 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | Paysign (PAYS) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/paysign-pays-q3-2026-earnings-call-transcript
  • N2 | 2026-11-09 | www.nasdaq.com | Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43% | https://www.nasdaq.com/articles/paysign-reports-record-third-quarter-2026-revenue-308-million-43
  • N3 | 2026-09-18 | www.nasdaq.com | Has CBIZ (CBZ) Outpaced Other Business Services Stocks This Year? | https://www.nasdaq.com/articles/has-cbiz-cbz-outpaced-other-business-services-stocks-year
  • N4 | 2026-08-28 | www.nasdaq.com | Paysign Targets $117M Revenue as Patient-Affordability Business Surges | https://www.nasdaq.com/articles/paysign-targets-117m-revenue-patient-affordability-business-surges
  • N5 | 2026-08-13 | www.nasdaq.com | Are Business Services Stocks Lagging Paysign (PAYS) This Year? | https://www.nasdaq.com/articles/are-business-services-stocks-lagging-paysign-pays-year
  • N6 | 2026-08-06 | www.nasdaq.com | Paysign Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/paysign-q2-earnings-call-highlights
  • N7 | 2026-05-14 | www.nasdaq.com | Paysign PAYS Q1 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/paysign-pays-q1-2026-earnings-call-transcript
  • N8 | 2026-05-13 | www.nasdaq.com | Paysign Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/paysign-q1-earnings-call-highlights
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine